Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024
Type: Fireside Chat Presentation
Date/Time: May 14, 2024, 9:30 a.m. EDT
BofA Securities 2024 Healthcare Conference – May 13-16, 2024
Type: Fireside Chat Presentation
Date/Time: May 16, 2024, 8:40 a.m. PDT
TIDES USA 2024 – May 14-17, 2024
Title: Preclinical Profile of ARO-SOD1, an siRNA Therapy for SOD1-ALS
Date/Time: May 16, 2024, 3:00 p.m. EDT
Presenter: Christine Esau, Ph.D.
Session: Oligonucleotide Chemistry, Mechanisms and Preclinical
Lesen Sie auch
Title: Novel TRiMTM Platform for Delivery of RNAi Therapeutics to Adipose Tissue
Date/Time: May 17, 2024, 9:00 a.m. EDT
Presenter: Tao Pei, Ph.D.
Session: Delivery of Macromolecules
American Thoracic Society (ATS) 2024 International Conference – May 17-22, 2024
Title: A First-in-Human Study of ARO-RAGE, a Novel Inhaled RNA-Interference Therapy for Asthma
Date/Time: May 19, 2024, 11:30 a.m. PDT
Type: Late-Breaking Poster
Title: A lung-targeted therapeutic siRNA against highly conserved viral M1 mRNAs effectively limits highly pathogenic influenza A infection in mice
Date/Time: May 20, 2024, 11:30 a.m.
PDT
Type: Poster
Title: Lung-targeted RNAi molecules silence human TSLP expression in PCLS cultures and humanized mice and suppress pulmonary allergic inflammation
Date/Time: May 20, 2024, 11:30 a.m.
PDT
Type: Poster
37th International Conference on Antiviral Research (ICAR2024) – May 20-24, 2024
Title: Liver-targeted therapeutic siRNAs against highly conserved yellow fever virus genomic sequences effectively limit infection and mortality in a hamster model
Date/Time: May 22,
2024, 10:45 a.m. AEST
Presenter: Justin Julander, Ph.D.
Session: Lipid Lowering via Novel Pathways
European Atherosclerosis Society (EAS) 92nd Congress – May 26-29, 2024
Title: PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
Date/Time: May 28, 2024, 12:04 p.m. CEST
Presenter: Christie M Ballantyne, M.D.
Session: New Therapeutics
Title: PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA
(SHTG), SHASTA-2 FINAL RESULTS
Date/Time: May 28, 2024, 2:49 p.m. CEST
Presenter: Daniel Gaudet, M.D., Ph.D.
Session: SaaG Session: The Enigmas of TG-rich Lipoproteins
Title: ZODASIRAN SILENCES HEPATIC ANGPTL3 LEADING TO DEEP AND DURABLE REDUCTIONS IN ATHEROGENIC LIPIDS AND LIPOPROTEINS IN MIXED DYSLIPIDEMIA PATIENTS: FINAL RESULTS FROM ARCHES-2, DOUBLE-BLIND PERIOD